Cancer research pledge
Why cancer research matters to Leyra
Leyra is built around reflection, perspective and the belief that ordinary days matter. The pledge is part of that same purpose: a quiet, transparent way for paid growth to support cancer research and support causes as Leyra grows.
Plus: 10p in every £1 received
Pro: 20p in every £1 received
Ledger reported publicly
No partnership claim
The story
A calm product with a life-affirming purpose
The honest story is simple: life can be fragile, and it is worth living with a little more attention, kindness and intention. Leyra helps people pause before the day carries them away.
The pledge does not make the product more important than it is. Leyra still has to earn trust by being useful, private and gentle. The giving-back layer is there because the product's growth should do some wider good too.
No personal medical story is published here unless explicitly approved. This page uses only Leyra's confirmed public pledge wording and public cancer-risk sources.
Public context
Nearly 1 in 2 is a serious enough reason
Cancer Research UK’s lifetime-risk statistics report that the estimated lifetime risk of being diagnosed with cancer is nearly 1 in 2 for people born in the UK in 1961.
That public context is enough to explain the direction without using fear or pressure. Leyra should never make someone feel guilty for staying on the free plan or for choosing not to subscribe.
Read the Cancer Research UK lifetime-risk source
How the pledge works
Simple enough to understand, cautious enough to report
Leyra uses clear pledge wording rather than vague charity language. The pledge is calculated from what Leyra receives from paid subscriptions after normal payment adjustments.
10p
Plus pledge
For every £1 Leyra receives from Plus subscriptions, 10p is pledged towards cancer research and support causes.
20p
Pro pledge
For every £1 Leyra receives from Pro subscriptions, 20p is pledged towards cancer research and support causes.
Ledger
Public reporting
The giving-back page separates calculated pledge, recorded donations, outstanding balance and evidence status.
Boundaries
What Leyra will and will not claim
No implied partnership
Leyra is not endorsed by Cancer Research UK and does not use charity logos, trademarks or official partnership wording.
No guilt selling
The pledge is part of Leyra's purpose, not a pressure tactic. People should be able to try Leyra calmly and choose paid plans only if the product is useful to them.
No professional advice
Leyra does not provide medical advice; readings and pledge pages are not medical, legal, financial, emergency or professional advice.
Proof, not pressure
How Leyra will show the giving-back record
The pledge should feel transparent, not emotionally manipulative. The public record separates what is pledged, what is donated and what is still awaiting evidence.
See pledge status
Plain amounts
Plus and Pro pledge rates are shown clearly, without percentage-of-profit wording or hidden calculation rules.
Clear status
Held, pending and donated amounts must be described as different states, not blended into one bigger claim.
Careful claims
Leyra will not claim a named charity partnership, endorsement or logo permission unless that permission exists.
FAQ
Questions about the pledge
Why cancer research and support causes?
Because cancer affects many families, and because Leyra's broader message is life-affirming: pause, reflect, live more intentionally, and do some good as the product grows.
Does the pledge mean Leyra is a charity?
No. Leyra is a commercial subscription product with a giving-back pledge attached to paid subscription receipts.
Why avoid naming a specific recipient for now?
Until charity permissions, reporting and commercial-participation checks are complete, Leyra keeps public wording generic and avoids implying a named charity partnership.
Where is the proof?
The giving-back page is the public ledger. It shows published periods, pledge calculation, recorded donation, outstanding pledged balance and evidence status when entries are ready.
